X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs UNICHEM LAB - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA UNICHEM LAB ELDER PHARMA/
UNICHEM LAB
 
P/E (TTM) x -0.2 -64.7 - View Chart
P/BV x 0.1 0.7 13.9% View Chart
Dividend Yield % 0.0 2.3 -  

Financials

 ELDER PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
UNICHEM LAB
Mar-18
ELDER PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs380382 99.5%   
Low Rs188234 80.3%   
Sales per share (Unadj.) Rs491.2116.3 422.4%  
Earnings per share (Unadj.) Rs-3.2-18.9 16.8%  
Cash flow per share (Unadj.) Rs14.4-11.7 -122.7%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %01.6 0.0%  
Book value per share (Unadj.) Rs376.5381.0 98.8%  
Shares outstanding (eoy) m20.5470.34 29.2%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.62.6 21.8%   
Avg P/E ratio x-89.3-16.3 548.3%  
P/CF ratio (eoy) x19.7-26.2 -75.1%  
Price / Book Value ratio x0.80.8 93.3%  
Dividend payout %0-26.4 0.0%   
Avg Mkt Cap Rs m5,83321,668 26.9%   
No. of employees `000NA2.3 0.0%   
Total wages/salary Rs m2,1792,006 108.6%   
Avg. sales/employee Rs ThNM3,587.8-  
Avg. wages/employee Rs ThNM880.0-  
Avg. net profit/employee Rs ThNM-583.7-  
INCOME DATA
Net Sales Rs m10,0898,180 123.3%  
Other income Rs m257610 42.1%   
Total revenues Rs m10,3468,790 117.7%   
Gross profit Rs m-792-1,320 60.0%  
Depreciation Rs m361505 71.5%   
Interest Rs m2,75680 3,441.1%   
Profit before tax Rs m-3,653-1,295 282.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m12533 374.5%   
Profit after tax Rs m-65-1,331 4.9%  
Gross profit margin %-7.8-16.1 48.6%  
Effective tax rate %-3.4-2.6 132.8%   
Net profit margin %-0.6-16.3 4.0%  
BALANCE SHEET DATA
Current assets Rs m9,24023,318 39.6%   
Current liabilities Rs m9,9984,635 215.7%   
Net working cap to sales %-7.5228.4 -3.3%  
Current ratio x0.95.0 18.4%  
Inventory Days Days46122 38.0%  
Debtors Days Days60121 49.3%  
Net fixed assets Rs m10,1248,163 124.0%   
Share capital Rs m206141 146.2%   
"Free" reserves Rs m5,58226,660 20.9%   
Net worth Rs m7,73426,801 28.9%   
Long term debt Rs m4,8893 148,151.5%   
Total assets Rs m22,88231,890 71.8%  
Interest coverage x-0.3-15.2 2.1%   
Debt to equity ratio x0.60 513,425.9%  
Sales to assets ratio x0.40.3 171.9%   
Return on assets %11.8-3.9 -299.8%  
Return on equity %-0.8-5.0 17.0%  
Return on capital %22.3-4.5 -491.2%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m3074,356 7.0%   
Fx outflow Rs m1250-   
Net fx Rs m1814,356 4.2%   
CASH FLOW
From Operations Rs m11,754-1,123 -1,046.3%  
From Investments Rs m-56116,487 -3.4%  
From Financial Activity Rs m-6,762-8,811 76.7%  
Net Cashflow Rs m4,4326,552 67.6%  

Share Holding

Indian Promoters % 39.6 50.1 79.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 15.1 49.7%  
FIIs % 16.8 3.0 560.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 31.7 113.9%  
Shareholders   16,479 20,176 81.7%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   AUROBINDO PHARMA  MERCK LTD  SANOFI INDIA  J.B.CHEMICALS  ORCHID PHARMA LTD  

Compare ELDER PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

UNICHEM LAB Announces Quarterly Results (1QFY19); Net Profit Down 1479.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, UNICHEM LAB has posted a net profit of Rs 207 m (down 1479.6% YoY). Sales on the other hand came in at Rs 2 bn (down 35.9% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB Announces Quarterly Results (4QFY18); Net Profit Down 91.1% (Quarterly Result Update)

Jun 14, 2018 | Updated on Jun 14, 2018

For the quarter ended March 2018, UNICHEM LAB has posted a net profit of Rs 28 m (down 91.1% YoY). Sales on the other hand came in at Rs 2 bn (down 40.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS